Galecto’s Oral Galectin-3 Inhibitor GB1211 Well Tolerated in Phase I Clinical Data Presented Recently at Several Scientific Conferences
Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today that its potent and selective oral small molecule galectin-3 inhibitor, GB1211, was well tolerated in pre-clinical and Phase 1 studies and is ready to start a Phase 2a clinical study to treat liver fibrosis in Non-Alcoholic SteatoHepatitis (NASH).
